



## Biogen to Participate in the Stifel 2022 CNS Days

March 17, 2022

Cambridge, MA, -- [Biogen Inc.](#) (Nasdaq: BILB) announced today that Priya Singhal, M.D., M.P.H., Head of Global Safety and Regulatory Sciences and Interim Head of R&D, will participate in the Stifel 2022 CNS Days. The webcast will be live on Monday, March 28, 2022, at 10:15 a.m. ET. To access the live webcast, please visit the Investors section of Biogen's website at [investors.biogen.com](#). An archived version of the webcast will be available following the presentation.

### About Biogen

As pioneers in neuroscience, Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological diseases as well as related therapeutic adjacencies. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today, Biogen has a leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, and is providing the first and only approved treatment to address a defining pathology of Alzheimer's disease. Biogen is also commercializing biosimilars and focusing on advancing the industry's most diversified pipeline in neuroscience that will transform the standard of care for patients in several areas of high unmet need.

In 2020, Biogen launched a bold 20-year, \$250 million initiative to address the deeply interrelated issues of climate, health, and equity. Healthy Climate, Healthy Lives™ aims to eliminate fossil fuels across the company's operations, build collaborations with renowned institutions to advance the science to improve human health outcomes, and support underserved communities.

The company routinely post information that may be important to investors on our website at [www.biogen.com](#). To learn more, please visit [www.biogen.com](#) and follow Biogen on social media – [Twitter](#), [LinkedIn](#), [Facebook](#), [YouTube](#).

**Contact:**  
Karen Jewell  
Investor Relations  
Biogen  
781.464.2442